Expression of CCL2 is significantly different in five breast cancer genotypes and predicts patient outcome.

Breast cancer is one of the most common malignancies in women. Current treatment of breast cancer is mainly based on clinicopathological characteristics, and is not sufficiently customized for individual cases. The concept of genotyping in breast cancer was first proposed in 2001.

Associations between vitamin D receptor polymorphisms and breast cancer risk.

Many epidemiologic studies have investigated the association between vitamin D receptor (VDR) gene polymorphisms and breast cancer risk, but the results were inconsistent. We performed a meta-analysis of 31 studies on VDR polymorphisms, including FokI, BsmI, TaqI, and ApaI, and breast cancer risk published before May 2013. For FokI, the allele of f was found to be associated with increased risk of breast cancer compared with F (OR, 1.

[Clinical-pathological characteristics and survival of triple negative breast cancer].

Objective: To investigate the clinical-pathological characteristics of triple negative breast cancer.

Methods: The clinical-pathological characteristics of 690 breast cancer patients, all females, 127 being estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor (HER)-2 triple negative, were analyzed.

Results: The expression rate of P53, a tumor suppressor gene, of the triple negative breast cancer patients was 71.